Objectives: The role of follow-up venous duplex ultrasound (DUS) imaging after acute lower extremity deep vein thrombosis (DVT) remains unclear, yet it is commonly performed. Our primary objective was to determine the association between the presence of residual venous obstruction (RVO) and DVT recurrence or propagation (rDVT). Secondary objectives included finding risk factors associated with RVO and the role of follow-up DUS imaging.
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Methods:
We conducted a retrospective study of patients diagnosed with DVT by DUS imaging at our institution from 2011 to 2013 who received a follow-up study. Patient demographics, risk factors, medications, and DUS findings were recorded. Ten segments from the common femoral to distal calf veins were checked for presence of RVO, DVT propagation, and recurrence. RVO was defined as any nonacute venous obstruction with >40% of the luminal diameter remaining during compression or presence of chronic thrombus. rDVT was measured as a new acute DVT in the same previously involved segment or involvement of a new segment in the same extremity.
Results: A total of 199 lower extremities representing 182 patients met the inclusion criteria. RVO was noted in 53.2%. Mean (standard error of the mean) DUS follow-up was 254.2 6 23 days. rDVT rate was 16.4%. Patients with previous venous thromboembolism or thrombophilia had a higher risk of developing RVO (RR ¼ 1.5, P ¼ .003; RR ¼ 1.6, P ¼ .02, respectively). Extremities with initial clot burden of three or more segments had an increased risk of RVO on follow-up DUS (RR ¼ 1.4; P ¼ .02). A total of 74 extremities had multiple serial DUS, representing 72 patients. Extremities in this subgroup with presence of RVO on the first follow-up DUS had increased risk of rDVT on subsequent DUS (RR ¼ 6.4; P < .001). RVO in three or more segments also predicted rDVT (RR ¼ 2.25; P ¼ .04).
Conclusions: Extremities with larger initial clot burden increased the risk of subsequent RVO. The presence of RVO, as well as the number of involved segments on follow-up DUS, increased the risk of rDVT. Our results suggest that follow-up DUS after acute DVT may identify patients with presence of RVO and increased RVO burden who are at increased risk for rDVT and may help guide the duration of anticoagulation therapy. Objectives: Dialysis access in the obese is a common problem. The VWING device (Vital Access, Salt Lake City, Utah) is a novel technology facilitating difficult or deep cannulation when the fistula is 4 to 13 mm deep. One or two devices can be surgically placed on the fistula after maturation as needle guides to allow fistula access while avoiding transposition. This data set illustrates real-world use of the device.
Methods: Data were obtained from a retrospective review of a prospective database maintained by Vital Access, tracking devices implanted from May 1, 2012, to November 1, 2016. All patients with at least 30 days' follow-up or death within 30 days were included in the analysis. The c 2 test and multivariable regression in Stata (StataCorp LP, College Station, Tex) were used for analysis.
Results: Included were 655 patients. Six deaths within 30 days (0.9%) were not thought to be due to devices. Average follow-up time was 337 days (range, 9-1464 days). Accesses modified by VWING were brachiocephalic, 64.8%; brachiobasilic, 16.2%; radiocephalic, 13.2%; previously transposed fistula, 4.3%; and graft, 1.3%. Average time to first sharp cannulation after implantation was 68 days (median, 48 days). Time to blunt cannulation averaged 75 days (median, 59 days). Average duration of VWING use at last follow-up was 203 days (range, 0-1200 days). When catheter removal was documented, it occurred an average of 116 days (median, 95 days) after VWING implantation. A total of 353 patients (53.2%) were using at least one device at last follow-up. Percent VWINGS in use by year of implantation were 2013, 38%; 2014, 43%; 2015, 53%; and 2016, 65%. Reasons VWINGs were not used in 306 patients included 36% cannulation problems, 27.5% fistula failure, 10.4% predialysis, 7.8% another modality used, 5.5% patient refusal, 3.9% flow issues, and 2% infection. Surgeons who had placed devices in more than one patient were more likely to have VWINGS in use at last follow-up (P < .007). No differences in use were found between clinic providers. A total of 77 (12%) patients had at least one device removed. Reasons for explantation were 28.6% infection, 26% cannulation difficulties, 11.7% device moved, 11.7% no longer needed, 6.5% excessive scarring, and 15.6% unknown. A total of 44 patients (6.7%) had a secondary procedure, not including catheter placement. There were no known fistula failures due to device placement or removal. Fistula survival was 87%. Failure of 84 fistulas (12.8%) occurred an average of 254 days after implantation.
Conclusions: VWING devices facilitate cannulation in a difficult dialysis population. Use of the devices is safe and allows use of deep fistulas with smaller incisions than traditional superficialization.
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Outcomes of Forearm Loop Grafts and the
Results: Thirty-six fAVGs and 163 upper arm AVFs were created during the study period. In the fAVG cohort, 28 were inserted with ipsilateral cephalic and/or basilic upper arm vein <3 mm, and eight were inserted with ipsilateral upper arm vein $3 mm. Primary and cumulative patency of fAVG with $3 mm upper ipsilateral arm vein were similar to upper arm AVF (Table) . The primary and cumulative patency at 6 months and 1 year are noted in the Table. One-third (3 of 9) patients in the fAVG cohort with <3 mm cephalic and/or basilica vein experienced dilation of the upper arm ipsilateral cephalic and/or basilic veins to $3 mm after AVG failure. The average increase vein diameter was 0.7 6 1.3 mm. Reasons for not observing an increase of ipsilateral vein diameter after fAVG failure include <3 months of a patent forearm loop graft, stenting across the outflow vein across the elbow, and initial vein caliber <2 mm.
Conclusions: Our results demonstrate fAVG with $3 mm ipsilateral upper arm vein at time of insertion have similar patency to upper arm AVG, thereby preserving future HD access sites. In circumstances when upper arm vein is <3 mm, fAVG insertion may provide an additional benefit of increasing HD access sites via dilation of upper arm veins in one-third of patients. Objectives: Thoracic endovascular aortic repair (TEVAR) has become the treatment of choice for aortic dissections in many centers. While adequate proximal seal is a fundamental requisite for TEVAR, there are insufficient data on the impact of the proximal seal length on patient outcomes. The goal of this study was to describe the proximal seal zone achieved during TEVAR for aortic dissections as well as its effect on clinical outcomes and aortic remodeling.
Methods: A retrospective review was performed on all patients who underwent TEVAR for aortic dissections at a single institution from 2006 to 2016. Preoperative computed tomography (CT) was used to identify the entry tear, extent of dissection, and distances between the arch branches in three-dimensional centerline. Proximal seal zone length was calculated on postoperative imaging. Sequential postoperative CT scans were analyzed for remodeling of the true and false lumen aortic diameters over time. Clinical outcomes, including retrograde type A dissection (RTAD), death, and aortic reinterventions, were recorded.
Results: During the study period, 84 patients underwent TEVAR for aortic dissections. Indications for TEVAR were malperfusion (n ¼ 12), aneurysm (n ¼ 26), persistent pain (n ¼ 33), rupture (n ¼ 8), uncontrolled hypertension (n ¼ 2), and other (n ¼ 3). Mean follow-up was 14 months (range, 0-94 months). In 28 patients (33%), the aorta proximal to stent graft was without intramural hematoma, while the proximal seal zone in 56 patients (67%) was entirely in intramural hematoma. Proximal seal according to the manufacturers' instructions for use (2 cm of normal 
